Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betaseron in Multiple Sclerosis (BENEFIT Extension)
NCT00185211Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2002
- Primary completion
- May 2008
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of interferon beta in multiple sclerosis (MS), sponsored by Bayer. Primary endpoints: Time to Clinically Definite Multiple Sclerosis at 60 months, Time to Confirmed Expanded Disability Status Scale Progression at 60 months and 1 more. Started Aug 2002; status: completed.
02
Drugs
interferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00185211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185211.